A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma (NCT04980222)

🧪 Interventions in This Study

• Glofitamab (DRUG)
• Tocilizumab (DRUG)
• Doxorubicin (DRUG)
• Vincristine (DRUG)
• Prednisone (DRUG)
• Rituximab (DRUG)
• Cyclophosphamide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• City of Hope Comprehensive Cancer Center — Duarte, California
• Stanford Cancer Center — Stanford, California
• Stanford Cancer Institute Inpatient Investigational Pharmacy — Stanford, California
• University of Iowa — Iowa City, Iowa
• University of Michigan Health System — Ann Arbor, Michigan
• Washington University; Wash Uni. Sch. Of Med — St Louis, Missouri
• Memorial Sloan Kettering Bergen — Montvale, New Jersey
• Memorial Sloan Kettering Cancer Center at Westchester — East White Plains, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Baylor University Medical Center — Dallas, Texas
• Aarhus Universitetshospital Skejby — Aarhus N,
• Hopital Henri Mondor — Créteil,
• Centre Henri Becquerel — Rouen,
• Universitair Medisch Centrum Groningen — Groningen,
• Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii — Gdansk,
• Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku — Wroclaw,
• Hospital Clinic i Provincial de Barcelona — Barcelona, BARCELONA
• Hospital General Universitario Gregorio Marañon — Madrid, Madrid
• Hospital Univ. 12 de Octubre; Servicio de Hematologia — Madrid, Madrid
• Hospital Clinico Universitario de Salamanca — Salamanca, SALAMANCA

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma

• A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
• A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California
• Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma — Calgary, Alberta
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma — Anchorage, Alaska
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant — New York, New York
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL — Chapel Hill, North Carolina

Explore by condition: All Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.